Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + nab-paclitaxel + trastuzumab as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer
ChiCTR2500100648Phase 4Not yet recruiting
- Sponsor
- Huaihe Hospital of Henan University
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pyrotinib, paclitaxel and trastuzumab in breast cancer, sponsored by Huaihe Hospital of Henan University. Primary endpoint: Pathologic complete response. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500100648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100648.